Doporučení pro diagnostiku a léčbu chronického srdečního selhání

65. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The
effect of angiotensin-converting-enzyme inhibition on
diabetic nephropathy. The Collaborative Study Group.
Published erratum appears in New Engl J Med
1993;330:152. New Engl J Med 1993;329:1456–62.
66. Linde C. Implantable cardioverter-defibrillator treatment
and resynchronisation in heart failure. Heart
2004;90:231–4.
67. Ljungman S, Kjekshus J, Swedberg K. Renal function
in severe congestive heart failure during treatment
with enalapril (the Cooperative North Scandinavian
Enalapril Survival Study [CONSENSUS] Trial). Am
J Cardiol 1992;70:479–87.
68. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in
congestive heart failure. Relationship of cardiac index
to kidney function. Drugs 1990;39 Suppl 4:10–21.
69. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction
and the risk of stroke after myocardial infarction.
New Engl J Med 1997;336:251–7.
70. López-Sendón J, Swedberg K, McMurray J, et al.
Expert consensus document on beta-adrenergic receptor
blockers. Eur Heart J 2004;25:1341–62.
71. Lucas C, Johnson W, Hamilton MA, et al. Freedom
from congestion predicts good survival despite previous
class IV symptoms of heart failure. Am Heart
J 2000;140:840–7.
72. Lukl J, Heinc P, a kol. Moderní léãba arytmií. Praha:
Grada Publishing, 2001:173–7.
73. Lupínek P. V˘znam a léãba anemie u chronického
srdeãního selhání. Cor Vasa 2004;46:281–4.
74. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid
measurement of B-type natriuretic peptide in the
emergency diagnosis of heart failure. New Engl J Med
2002;347:161–7.
75. Major outcomes in high-risk hypertensive patients randomized
to angiotensin-converting enzyme inhibitor or
calcium channel blocker vs diuretic: The Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT). JAMA 2002;288:2981–97.
76. Málek F, Ignaszewski A. Nové léky pro terapii pokroãilého
srdeãního selhání. Cor Vasa 2004;46:221–5.
77. Mancini DM, Eisen H, Kussmaul W, et al. Value of
peak exercise oxygen consumption for optimal timing
of cardiac transplantation in ambulatory patients with
heart failure. Circulation 1991;83:778–86.
78. Masoudi FA, Wolfe P, Havranek EP, et al. Aspirin use
in older patients with heart failure and coronary
artery disease: national prescription patterns and
relationship with outcomes. J Am Coll Cardiol
2005;46:955–62.
79. Massie BM, Krol WF, Ammon SE, et al. The warfarin
and antiplatelet therapy in heart failure trial (WATCH):
rationale, design, and baseline patient characteristics.
J Card Fail 2004;10:101–12.
80. MERIT-HF Study Group. Effect of metoprolol CR/XL
in chronic heart failure. Metoprolol CR/XL randomised
intervention trial in congestive heart failure
(MERIT-HF). Lancet 1999;353:2001–7.
81. Morgan JM. The MADIT II and COMPANION studies:
will they affect uptake of device treatment Heart
2004;90:243–5.
82. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic
implantation of a defibrillator in patients with myocardial
infarction and reduced ejection fraction. New Engl
J Med 2002;346:877–83.
83. Moss AJ. MADIT-II and its implications. Eur Heart
J 2003;24:16–8.
84. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence
of heart failure and left ventricular dysfunction in the
general population. Eur Heart J 1999;20:447–55.
85. Murdoch DR, Love MP, Robb SD, et al. Importance of
heart failure as a cause of death. Changing contribution
to overall mortality and coronary heart disease
mortality in Scotland 1979–92. Eur Heart J 1998;
19:1829-35.
86. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA,
Quinones MA. Doppler tissue imaging: A noninvasive
technique for evaluation of left ventricular relaxation
and estimation of filling pressures. J Am Coll Cardiol
1997;30:1527–33.
87. Okada RD, Hager WD, Graves PE, Mayersohn M, Perrier
DG, Marcus FI. Relationship between plasma concentration
and dose of digoxin in patients with and without
renal impairment. Circulation 1978;58:1196–203.
88. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical
utility of Doppler echocardiography and tissue Doppler
imaging in the estimation of left ventricular filling
pressures. Circulation 2000;102:1788–94.
89. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol
on survival in severe chronic heart failure. New
Engl J Med 2001;344:1651–8.
90. Packer M, Poole-Wilson PA, Armstrong PW, et al.
Comparative effects of low and high doses of the angiotensin-converting
enzyme inhibitor, lisinopril, on morbidity
and mortality in chronic heart failure. ATLAS
Study Group. Circulation 1999;100:2312–8.
91. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS.
Global strategy for the diagnosis, management, and
prevention of chronic obstructive pulmonary disease:
National Heart, Lung, and Blood Institute and World
Health Organization Global Initiative for Chronic
Obstructive Lung Disease (GOLD): executive summary.
Res Care 2001;46:798–825.
92. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective
aldosterone blocker, in patients with left ventricular
dysfunction after myocardial infarction. New
Engl J Med 2003;348:1309–21.
93. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone
on morbidity and mortality in patients with
severe heart failure. Randomized Aldactone Evaluation
Study Investigators. New Engl J Med 1999;341:709–17.
94. Poole-Wilson PA, Swedberg K, Cleland JG, et al.
Comparison of carvedilol and metoprolol on clinical
outcomes in patients with chronic heart failure in the
Carvedilol Or Metoprolol European Trial (COMET):
randomised controlled trial. Lancet 2003;362:7–13.
95. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task
force on sudden cardiac death of the European Society
of Cardiology. Eur Heart J 2001;22:1374–50.
96. Rambausek M, Ritz E. Digitalis in chronic renal insufficiency.
Blood Purif 1985;3:4–14.
97. Rathore SS, Wang Y, Krumholz HM. Sex-based differences
in the effect of digoxin for the treatment
of heart failure. New Engl J Med 2002;347:1403–11.
98. Rathore SS, Curtis JP, Wang Y, et al. Association of
serum digoxin concentration and outcomes in patients
with heart failure. JAMA 2003;289:871–8.
99. Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity
of clinical diagnosis of heart failure in primary
health care. Eur Heart J 1991;12:315–21.
100. Remme WJ. Should ACE inhibitors Always be First –
Line Therapy in Heart Fauilure Lessons from the
CARMEN Study. Cardiovasc Drugs Ther 2003;17:107–9.
101. Render ML, Weinstein AS, Blaustein AS. Left ventricular
dysfunction in deteriorating patients with chronic
obstructive pulmonary disease. Chest 1995;107:162–8.
102. Reyes AJ, Taylor SH. Diuretics in Cardiovascular
Therapy: The new Clinicopharmacological Bases That
Matter. Cardiovasc Drug Ther 1999;13:371–98.
103. Rimondini A, Cipolla CM, Della Bella P, et al.
Hemofiltration as short-term treatment for refractory
congestive heart failure. Am J Med 1987;83:43–8.
104. Rosolova H, Cech J, Simon J, et al. Short to long term
mortality of patiens hospitalized in the Czech Republic
– report from the Euro Heart Failure Survey. Eur
J Heart Fail 2005;7:780–3.
Cor Vasa 2007;49(1):Kardio K 33